• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数

Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.

作者信息

Panagiotopoulos Nikolaos, Wolfson Tanya, Harris David T, Batakis Danielle, Agni Rashmi, Ceriani Lael, Covarrubias Yesenia, Hamilton Gavin, Middleton Michael S, Martins Vitor F, Gamst Anthony C, Oechtering Thekla H, Sappenfield Ryan, Horgan Santiago, Grunvald Eduardo, Funk Luke M, Jacobsen Garth R, Lidor Anne O, Goodman James A, Khoury Sami B, Sirlin Claude B, Reeder Scott B

机构信息

Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Computational and Applied Statistical Laboratory (CASL), San Diego Supercomputer Center, University of California San Diego, San Diego, California, USA.

出版信息

Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.

DOI:10.1097/HEP.0000000000001318
PMID:40132140
Abstract

BACKGROUND AND AIMS

Prior work has shown that MRI-derived proton density fat fraction (PDFF) can diagnose metabolic dysfunction-associated steatotic liver disease (MASLD) noninvasively, but there is a paucity of data on the performance of PDFF to classify more advanced forms of the MASLD spectrum. The purpose of this study was to assess the diagnostic performance of PDFF for the diagnoses of MASLD, metabolic dysfunction-associated steatohepatitis (MASH), and fibrotic MASH in adults with obesity undergoing bariatric surgery, using contemporaneous intraoperative liver biopsy as a reference.

APPROACH AND RESULTS

PDFF was evaluated alone and with other potential classifiers (imaging, serum and anthropometric), using Bayesian Information Criterion-based stepwise logistic regression models. Areas under the receiver operating characteristic (ROC) curves (AUC) were computed for all models and single classifiers. Cross-validated sensitivity and specificity were calculated at Youden-based PDFF classification thresholds. Data analysis from 140 patients demonstrated that PDFF was the most accurate single classifier, with high AUC for MASLD (0.95), MASH (0.85), and fibrotic MASH (0.82) (all p <0.001). Multivariable models, including PDFF, outperformed those without PDFF. The Youden-based threshold for PDFF was 4.4% for MASLD (sensitivity: 87%, specificity: 86%), 6.9% for MASH (sensitivity: 77%, specificity: 66%), and 13.5% for fibrotic MASH (sensitivity: 67%, specificity: 85%).

CONCLUSIONS

PDFF was the most accurate single classifier for diagnosing MASLD, MASH, and fibrotic MASH. The most accurate multivariable classification models for MASLD, MASH, and fibrotic MASH included PDFF, demonstrating the central importance of PDFF for noninvasive assessment of the MASLD spectrum.

摘要

背景与目的

先前的研究表明,磁共振成像衍生的质子密度脂肪分数(PDFF)可用于无创诊断代谢功能障碍相关脂肪性肝病(MASLD),但关于PDFF对MASLD谱系中更晚期形式进行分类的性能数据较少。本研究的目的是,以同期术中肝活检为参考,评估PDFF在接受减肥手术的肥胖成人中诊断MASLD、代谢功能障碍相关脂肪性肝炎(MASH)和纤维化MASH的诊断性能。

方法与结果

使用基于贝叶斯信息准则的逐步逻辑回归模型,单独评估PDFF以及与其他潜在分类器(影像学、血清学和人体测量学)联合评估。计算所有模型和单个分类器的受试者操作特征(ROC)曲线下面积(AUC)。在基于约登指数的PDFF分类阈值处计算交叉验证的敏感性和特异性。对140例患者的数据分析表明,PDFF是最准确的单个分类器,对MASLD(0.95)、MASH(0.85)和纤维化MASH(0.82)具有较高的AUC(均p<0.001)。包括PDFF的多变量模型优于不包括PDFF的模型。基于约登指数的PDFF诊断MASLD的阈值为4.4%(敏感性:87%,特异性:86%),诊断MASH的阈值为6.9%(敏感性:77%,特异性:66%),诊断纤维化MASH的阈值为13.5%(敏感性:67%,特异性:85%)。

结论

PDFF是诊断MASLD、MASH和纤维化MASH最准确的单个分类器。诊断MASLD、MASH和纤维化MASH最准确的多变量分类模型均包括PDFF,这表明PDFF在无创评估MASLD谱系中至关重要。

相似文献

1
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
2
Nonalcoholic Fatty Liver非酒精性脂肪肝
3
Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.普通人群中风险 MASH、MetALD 和酒精相关脂肪性肝病的流行情况。
Aliment Pharmacol Ther. 2024 May;59(10):1271-1281. doi: 10.1111/apt.17958. Epub 2024 Mar 19.
4
Metabolic Dysfunction-Associated Steatotic Liver Disease at Quantitative US: International Prospective Study.定量超声检查下代谢功能障碍相关性脂肪性肝病:国际前瞻性研究
Radiology. 2025 Jul;316(1):e242564. doi: 10.1148/radiol.242564.
5
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.MASH 消退指数:一种用于检测 MASH 组织学消退的非侵入性评分的开发与验证
Gut. 2024 Jul 11;73(8):1343-1349. doi: 10.1136/gutjnl-2023-331401.
6
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.荷兰肥胖症队列中代谢功能障碍相关脂肪性肝病(MASLD)、非酒精性脂肪性肝炎(MASH)和肝纤维化患病率的评估。
PLoS One. 2025 Jun 24;20(6):e0324813. doi: 10.1371/journal.pone.0324813. eCollection 2025.
7
Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis.磁共振弹性成像与FIB-4(MEFIB)指数及振动控制瞬时弹性成像在显著代谢功能障碍相关脂肪性肝病肝纤维化中的比较
Can Liver J. 2024 Dec 19;7(4):419-426. doi: 10.3138/canlivj-2024-0007. eCollection 2024 Dec.
8
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.水飞蓟素用于患有代谢功能障碍相关脂肪性肝病的成年人。
Cochrane Database Syst Rev. 2025 Jun 24;6(6):CD015524. doi: 10.1002/14651858.CD015524.pub2.
9
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis.减重干预可改善肥胖患者代谢功能障碍相关脂肪性肝炎:系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Jul;30(3):561-576. doi: 10.3350/cmh.2023.0384. Epub 2024 Jun 3.
10
Diagnostic Accuracy of Noninvasive Scores for Fibrotic MASH in a Cohort of Biopsy-proven MASLD Patients With Predominantly High BMI in the Primary Care Setting.在基层医疗环境中,对一组经活检证实、BMI主要偏高的MASLD患者,非侵入性评分对纤维化MASH的诊断准确性。
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102556. doi: 10.1016/j.jceh.2025.102556. Epub 2025 Mar 25.

本文引用的文献

1
Acquisition Efficiency and Technical Repeatability of Dual-Frequency 3D Vector MR Elastography of the Liver.肝脏双频三维矢量磁共振弹性成像的采集效率与技术重复性
J Magn Reson Imaging. 2025 Mar;61(3):1416-1425. doi: 10.1002/jmri.29493. Epub 2024 Jun 27.
2
Precision and Test-Retest Repeatability of Stiffness Measurement with MR Elastography: A Multicenter Phantom Study.磁共振弹性成像测量刚度的精度和测试-再测试重复性:一项多中心 phantom 研究。
Radiology. 2024 May;311(2):e233136. doi: 10.1148/radiol.233136.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.美国非酒精性脂肪性肝病的总体及亚组患病率和晚期肝纤维化患病率:2011 - 2018年美国国家健康与营养检查调查(NHANES)的最新全国估计数。
Ann Hepatol. 2024 Jan-Feb;29(1):101154. doi: 10.1016/j.aohep.2023.101154. Epub 2023 Sep 22.
5
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
6
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.基于磁共振弹性成像的肝脏硬度、脂肪分数和 T1 弛豫时间在识别 NASH 高危患者中的头对头比较。
Hepatology. 2023 Oct 1;78(4):1200-1208. doi: 10.1097/HEP.0000000000000417. Epub 2023 May 1.
7
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
8
Current therapies and new developments in NASH.非酒精性脂肪性肝炎的当前治疗方法与新进展
Gut. 2022 Jun 16;71(10):2123-34. doi: 10.1136/gutjnl-2021-326874.
9
The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.磁共振弹性成像联合质子密度脂肪分数对非酒精性脂肪性肝炎的诊断价值。
J Magn Reson Imaging. 2022 Aug;56(2):368-379. doi: 10.1002/jmri.28040. Epub 2021 Dec 25.
10
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.非侵入性方法用于成像肝脂肪变性及其在非酒精性脂肪性肝病中的临床重要性。
Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0. Epub 2021 Nov 23.